2629.HK
MIRXES-B
HK$12.41
+0.00%
2026-05-29
About MIRXES-B
Mirxes Holding Company Limited, a micro ribonucleic acid technology company, provides diagnostic solutions for the screening of cancer, cardiovascular, metabolic, and infectious diseases accessible across Singapore and China. The company offers GASTROClear, a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening; LUNGClear, a lung cancer screening product candidate; and Fortitude COVID-19 RT-qPCR test kits. It also researches, develops, and manufactures biotechnology, life, and medical science related products. The company was founded in 2014 and is headquartered in Singapore.
Key Fundamentals
Forward P/E
-18.00
EPS (TTM)
HK$-2.16
Revenue Growth (YoY)
9.5%
Profit Margin
0.0%
Debt/Equity
20.21
Price/Book
4.15
Market Cap
HK$3.70B
Avg Volume (10D)
Recent Breakout Signals
No recent breakout signals detected for 2629.HK.
Recent Price Range (60 Days)
60D High
HK$18.04
60D Low
HK$12.28
Avg Volume
3.5M
Latest Close
HK$12.41
Get breakout alerts for 2629.HK
Sign up for Breakout Scanner to receive daily notifications when 2629.HK triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
MIRXES-B (2629.HK) is listed on the Hong Kong Exchanges (HKEX). Breakout Scanner monitors 2629.HK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. 2629.HK operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.